M. Kalos

M. Kalos, S. Forman, M. Jensen, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells

F. Bushman, B. Levine, M. Kalos, 2012, Science Translational Medicine.

CD19-Redirected Chimeric Antigen Receptor T (CART19) Cells Induce a Cytokine Release Syndrome (CRS) and Induction of Treatable Macrophage Activation Syndrome (MAS) That Can Be Managed by the IL-6 Antagonist Tocilizumab (toc).

D. Teachey, S. Grupp, D. Porter, 2012 .

A First-In-Human Clinical Trial of Adoptive Therapy Using CD19-Specific Chimeric Antigen Receptor Re-Directed T-Cells for Recurrent/Refractory Follicular Lymphoma.

M. Kalos, S. Forman, M. Jensen, 2007 .

Randomized, Phase II Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed, Refractory CLL

S. Grupp, D. Porter, B. Levine, 2013 .

HSP110 improves the anti-tumor effects of the cytotoxic T lymphocyte epitope E749-57 in mice: HSP110 as a peptide specific chaperone or adjuvant?

M. Kalos, 2010, Cancer biology & therapy.

T Cells Engineered With a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Produce Significant In Vivo Proliferation, Complete Responses and Long-Term Persistence Without Gvhd In Children and Adults With Relapsed, Refractory ALL

D. Teachey, D. Porter, B. Levine, 2013 .

Lymphoma Cells in Patients Undergoing Transplantation for AIDS-Related + Modified CD 34 − RNA-Based Gene Therapy for HIV with Lentiviral Vector

A. Krishnan, M. Kalos, J. Rossi, 2010 .

Molecular and Immunological Evaluation of the Transcription Factor SOX-4 as a Lung Tumor Vaccine Antigen

M. Kalos, R. Friedman, C. Bangur, 2004, The Journal of Immunology.

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.

Bernd Hauck, Bruce L Levine, David L Porter, 2013, The New England journal of medicine.

Identification of naturally processed CD8 T cell epitopes from prostein, a prostate tissue‐specific vaccine candidate

M. Kalos, R. Friedman, A. Spies, 2004, European journal of immunology.

Maude SL, Teachey DT, Porter DL, Grupp SA. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood. 2015;125(26):4017-4023.

D. Teachey, A. Seif, S. Grupp, 2016, Blood.

Adoptive immunotherapy for cancer

M. Kalos, M. Ruella, 2014, Immunological reviews.

Antiviral effects of autologous CD4 T cells genetically modified with a conditionally replicating lentiviral vector expressing long antisense to HIV.

F. Bushman, L. Montaner, E. Papasavvas, 2013, Blood.

Tumor antigen-specific T cells and cancer immunotherapy: current issues and future prospects.

M. Kalos, 2003, Vaccine.

T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia

David L. Porter, Adam Bagg, Bruce L. Levine, 2011, Science Translational Medicine.

T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans

B. Levine, M. Kalos, C. June, 2013, Cancer Immunology Research.

High Plasma Levels of MCP-1 and Eotaxin Provide Evidence for an Immunological Basis of Fibromyalgia

M. Kalos, J. Shively, Zhifang Zhang, 2008, Experimental biology and medicine.

The potent oncogene NPM-ALK mediates malignant transformation of normal human CD4(+) T lymphocytes.

M. Kalos, M. Wasik, C. Watt, 2013, The American journal of pathology.

Identification of Naturally Processed CD4 T Cell Epitopes from the Prostate-Specific Antigen Kallikrein 4 Using Peptide-Based In Vitro Stimulation1

R. Henderson, M. Kalos, S. Steen, 2002, The Journal of Immunology.

CD8+ T Cell Tolerance to a Tumor-associated Antigen Is Maintained at the Level of Expansion Rather than Effector Function

M. Kalos, P. Greenberg, B. Carson, 2002, The Journal of experimental medicine.

Accelerating the development of innovative cellular therapy products for the treatment of cancer.

Christopher G. Ramsborg, J. Bluestone, L. Butterfield, 2020, Cytotherapy.

T-cell immune monitoring assays to guide the development of new cancer vaccines

M. Welters, M. Kalos, C. Ottensmeier, 2011 .

Genetic modification of T-cell clones for therapy of human viral and malignant diseases.

B. Nelson, M. Kalos, M. Gavin, 1998, The cancer journal from Scientific American.

CLINICAL Cardiovascular toxicity and titin cross-reactivity of af ﬁ nity-enhanced T cells in myeloma and melanoma

G. Linette, A. Bagg, B. Levine, 2013 .

Antigen Immunotherapy of Tumors Expressing the T Cells or CTL + High-Affinity CD8 Peripheral Tissue Does Not Preclude Recovery of Expression of a Tolerizing Tumor Antigen in

M. Kalos, P. Greenberg, D. J. Hong, 2011 .

Expression of a Tolerizing Tumor Antigen in Peripheral Tissue Does Not Preclude Recovery of High-Affinity CD8+ T Cells or CTL Immunotherapy of Tumors Expressing the Antigen1

M. Kalos, P. Greenberg, D. J. Hong, 2001, The Journal of Immunology.

the Antigen CTL Immunotherapy of Tumors Expressing T Cells or + Recovery of High-Affinity CD8 Peripheral Tissue Does Not Preclude Expression of a Tolerizing Tumor Antigen in

M. Kalos, P. Greenberg, D. J. Hong, 2001 .

KOC (K Homology Domain Containing Protein Overexpressed in Cancer): A Novel Molecular Marker That Distinguishes Between Benign and Malignant Lesions of the Pancreas

R. Yantiss, K. Rock, D. Andersen, 2005, The American journal of surgical pathology.

Treatment with a VEGFR-2 antibody results in intra-tumor immune modulation and enhances anti-tumor efficacy of PD-L1 blockade in syngeneic murine tumor models

T. Doman, M. Kalos, J. Manro, 2022, PloS one.

Abstract 2753: The molecular basis of blocking the TIM-3 checkpoint with the LY3321367 mAb in cancer immunotherapy

J. Haidar, J. M. Sauder, M. Kalos, 2019, Cancer Chemistry.

Arthralgia among women taking aromatase inhibitors: is there a shared inflammatory mechanism with co-morbid fatigue and insomnia?

Jinbo Chen, A. DeMichele, M. Kalos, 2015, Breast Cancer Research.

Vitro Stimulation Antigen Kallikrein 4 Using Peptide-Based In Cell Epitopes from the Prostate-Specific Identification of Naturally Processed CD 4

R. Henderson, M. Kalos, S. Steen, 2002 .

Prostein expression is highly restricted to normal and malignant prostate tissues

S. Reed, George L. Wright, M. Kalos, 2004, The Prostate.

Characterization of 7A5: A Human CD137 (4-1BB) Receptor Binding Monoclonal Antibody with Differential Agonist Properties That Promotes Antitumor Immunity

J. Haidar, M. Kalos, Leyi Shen, 2020, Molecular Cancer Therapeutics.

Chimeric antigen receptor T-cell therapy to target hematologic malignancies.

M. Kalos, M. Ruella, S. Gill, 2014, Cancer research.

Adoptive immunotherapy for cancer or viruses.

B. Levine, M. Kalos, C. June, 2014, Annual review of immunology.

Identification and characterization of prostein, a novel prostate-specific protein.

S. Reed, M. Kalos, R. Houghton, 2001, Cancer research.

Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma.

Adam Bagg, Marcela V Maus, Bent K Jakobsen, 2013, Blood.

NY-ESO-1 specific TCR engineered T-cells mediate sustained antigen-specific antitumor effects in myeloma

J. E. Brewer, B. Levine, M. Kalos, 2015, Nature Medicine.

Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells.

M. Carroll, S. Grupp, D. Porter, 2014, Blood.

Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054

J. Haidar, M. Kalos, Leyi Shen, 2018, Journal of Immunotherapy for Cancer.

Treatment of advanced leukemia in mice with mRNA engineered T cells.

S. Grupp, M. Kalos, C. June, 2011, Human gene therapy.

Transfer of Specificity for Human Immunodeficiency Virus Type 1 into Primary Human T Lymphocytes by Introduction of T-Cell Receptor Genes

M. Kalos, S. Riddell, P. Greenberg, 2000, Journal of Virology.

Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies

D. Torigian, M. Soulen, B. Levine, 2013, Cancer Immunology Research.

Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells

Tyler J. Reich, F. Bushman, S. Carty, 2018, Nature.

The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade.

E. Rasmussen, P. Iversen, M. Kalos, 2018, Cell reports.

Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology.

M. Kalos, C. June, 2013, Immunity.

T cell assays and MIATA: the essential minimum for maximum impact.

M Roederer, S Janetzki, G Pawelec, 2012, Immunity.

"MIATA"-minimal information about T cell assays.

Sylvia Janetzki, Cedrik M Britten, Axel Hoos, 2009, Immunity.

De-Risking Immunotherapy: Report of a Consensus Workshop of the Cancer Immunotherapy Consortium of the Cancer Research Institute

Vanessa M. Hubbard-Lucey, S. H. van der Burg, E. Wherry, 2016, Cancer Immunology Research.

High-content molecular profiling of T-cell therapy in oncology

M. Kalos, Ruslan D. Novosiadly, R. Novosiadly, 2016, Molecular therapy oncolytics.

T cells targeting NY-ESO-1 demonstrate efficacy against disseminated neuroblastoma

S. Grupp, M. Kalos, C. June, 2016, Oncoimmunology.

Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade

P. Iversen, M. Kalos, G. Plowman, 2018, Journal of Immunotherapy for Cancer.

T-cell genetic modification for re-directed tumor recognition.

M. Kalos, S. Forman, Christine E. Brown, 2005, Cancer chemotherapy and biological response modifiers.

Development and implementation of a proficiency testing program for Luminex bead-based cytokine assays.

Heather E. Lynch, M. Kalos, T. Denny, 2014, Journal of immunological methods.

Improved anti-leukemia activities of adoptively transferred T cells expressing bispecific T-cell engager in mice

S. Grupp, M. Kalos, C. June, 2016, Blood Cancer Journal.

Mesothelin, a novel immunotherapy target for triple negative breast cancer

M. Kalos, C. June, H. Borghaei, 2012, Breast Cancer Research and Treatment.

Abstract A091: Targeting the TGFb pathway with galunisertib, a TGFbRI SMI, promotes antitumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint inhibition

M. Kalos, Xiaohong Xu, S. Castaneda, 2016 .

Targeting the TGFβ pathway with galunisertib, a TGFβRI SMI, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint inhibition

M. Kalos, Xiaohong Xu, S. Castaneda, 2015, Journal of Immunotherapy for Cancer.

IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients.

C. Desmarais, C. Carlson, J. Gastier-Foster, 2015, Blood.

Abstract PR06: T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 (CTL019) produce complete responses and long-term persistence without GVHD in children with relapsed, refractory ALL

D. Teachey, S. Grupp, B. Levine, 2014 .

RNA-Based Gene Therapy for HIV with Lentiviral Vector–Modified CD34+ Cells in Patients Undergoing Transplantation for AIDS-Related Lymphoma

Anitha Rao, John J. Rossi, Shirley Li, 2010, Science Translational Medicine.

Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials

H. Kohrt, J. Wolchok, L. Zitvogel, 2016, Journal of Immunotherapy for Cancer.

Microsphere-based multiplex analysis of DNA methylation in acute myeloid leukemia.

G. Wertheim, M. Carroll, M. Figueroa, 2014, The Journal of molecular diagnostics : JMD.

Chapter 18 – T Cell-Based Gene Therapy of Cancer

M. Kalos, S. Gill, 2015 .

T cell-based gene therapy of cancer.

Michael Kalos, M. Kalos, S. Gill, 2013, Translational research : the journal of laboratory and clinical medicine.

Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor

Xiaohong Xu, Philip W. Iversen, David K. Clawson, 2017, Oncotarget.

Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019 cells) Have Long-Term Persistence and Induce Durable Responses In Relapsed, Refractory CLL

S. Grupp, B. Levine, M. Kalos, 2013 .

Anti-CD123 Chimeric Antigen Receptor T Cells (CART-123) Provide A Novel Myeloablative Conditioning Regimen That Eradicates Human Acute Myeloid Leukemia In Preclinical Models

M. Carroll, S. Grupp, D. Porter, 2013 .

New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer

F. Marincola, J. Heath, S. Rosenberg, 2012, Journal of Translational Medicine.

Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond

L. J. Old, S. Janetzki, S. H. van der Burg, 2010, Cancer Immunology, Immunotherapy.

Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI)

Sylvia Janetzki, Axel Hoos, Pedro Romero, 2007, Cancer Immunology, Immunotherapy.

Position-independent transgene expression mediated by boundary elements from the apolipoprotein B chromatin domain

M. Kalos, R. Fournier, Michael Kalos, 1995, Molecular and cellular biology.

The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma

M. Kalos, C. June, M. Wasik, 2016, Clinical Cancer Research.

The Folate Pathway Inhibitor Pemetrexed Pleiotropically Enhances Effects of Cancer Immunotherapy

T. Doman, E. Rasmussen, M. Kalos, 2019, Clinical Cancer Research.

TUMORIGENESIS AND NEOPLASTIC PROGRESSION The Potent Oncogene NPM-ALK Mediates Malignant Transformation of Normal Human CD 4 D T Lymphocytes

M. Kalos, M. Wasik, C. Watt, 2017 .

Abstract 955: LY3200882, a novel, highly selective TGFβRI small molecule inhibitor

M. Kalos, Xiaohong Xu, B. Anderson, 2017 .

Identification of Chimeric Antigen Receptors That Mediate Constitutive or Inducible Proliferation of T Cells

Matthew J. Frigault, Jesse M. Platt, F. Johnson, 2015, Cancer Immunology Research.

Title: Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells Short Title: Constitutive CAR T-cell proliferation

Jihyun Lee, Matthew J. Frigault, Maria Ciocca Basil, 2015 .

Biomarkers for Immunostimulatory Monoclonal Antibodies in Combination Strategies for Melanoma and Other Tumor Types

Paolo A Ascierto, Michael Kalos, P. Ascierto, 2013, Clinical Cancer Research.

Miniatures Mesothelin-Speci fi c Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies

D. Torigian, M. Soulen, B. Levine, 2014 .

69. Adoptive T-cell Therapy for Malignancy in the Setting of Hematopoietic Cell Transplantation

M. Kalos, C. June, S. Forman, 2016 .

Identification of a Titin-Derived HLA-A1–Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3–Directed T Cells

Bent K Jakobsen, J. E. Brewer, Gabriela Plesa, 2013, Science Translational Medicine.

Muscle CARs and TcRs: turbo-charged technologies for the (T cell) masses

M. Kalos, 2011, Cancer Immunology, Immunotherapy.

Miniatures Immune Activation and a 9-Year Ongoing Complete Remission Following CD 40 Antibody Therapy and Metastasectomy in a Patient with Metastatic Melanoma

C. Desmarais, D. Torigian, K. Nathanson, 2014 .

Immune Activation and a 9-Year Ongoing Complete Remission Following CD40 Antibody Therapy and Metastasectomy in a Patient with Metastatic Melanoma

C. Desmarais, D. Torigian, K. Nathanson, 2014, Cancer Immunology Research.

Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors

M. Kalos, C. June, B. Jakobsen, 2012, Cancer Immunology, Immunotherapy.

Randomized, phase II dose optimization study of chimeric antigen receptor (CAR) modified T cells directed against CD19 in patients (pts) with relapsed, refractory (R/R) CLL.

S. Grupp, D. Porter, B. Levine, 2016 .

Development and application of a multiplexable flow cytometry‐based assay to quantify cell‐mediated cytolysis

M. Kalos, S. Mi, S. Blanchard, 2010, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

A critical assessment for the value of markers to gate-out undesired events in HLA-peptide multimer staining protocols

Sylvia Janetzki, Leah Price, Cedrik M Britten, 2011, Journal of Translational Medicine.

An integrative paradigm to impart quality to correlative science

M. Kalos, 2010, Journal of Translational Medicine.

A Dendritic Cell Vaccine Pulsed with Autologous Hypochlorous Acid-Oxidized Ovarian Cancer Lysate Primes Effective Broad Antitumor Immunity: From Bench to Bedside

Drew A. Torigian, Lana E. Kandalaft, George Coukos, 2013, Clinical Cancer Research.

Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans

B. Levine, M. Kalos, C. June, 2013 .

Chimeric Antigen Receptor T Cells Directed Against CD19 Induce Durable Responses and Transient Cytokine Release Syndrome in Relapsed, Refractory CLL and ALL

S. Grupp, D. Porter, B. Levine, 2012 .

Chimeric antigen receptor-engineered T cells in CLL: the next chapter unfolds

M. Kalos, 2016, Journal of Immunotherapy for Cancer.

Scholler Antigen Receptor T Cells Decade-Long Safety and Function of Retroviral-Modified Chimeric

F. Bushman, B. Levine, M. Kalos, 2012 .

Chimeric Antigen Receptor Therapy for B-cell Malignancies

D. Porter, B. Levine, M. Kalos, 2011, Journal of Cancer.

modified T cells - myeloablation using chimeric antigen receptor Preclinical targeting of human acute myeloid leukemia and

M. Carroll, S. Grupp, D. Porter, 2014 .

myeloablation using chimeric antigen receptor Preclinical targeting of human acute myeloid leukemia

M. Carroll, S. Grupp, D. Porter, 2014 .

Combination Immunotherapy after ASCT for Multiple Myeloma Using MAGE-A3/Poly-ICLC Immunizations Followed by Adoptive Transfer of Vaccine-Primed and Costimulated Autologous T Cells

B. Levine, M. Kalos, C. June, 2013, Clinical Cancer Research.

CART Targeting of Solid Tumors: More Pieces to the Puzzle

M. Kalos, 2018, Clinical Cancer Research.

Correction to: Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054

J. Haidar, M. Kalos, Leyi Shen, 2018, Journal of Immunotherapy for Cancer.

Effective targeting of primary human acute myeloid leukemia using anti-CD123 chimeric antigen receptor engineered T cells

M. Carroll, S. Grupp, D. Porter, 2013 .

Abstract 4549: Pemetrexed enhances anti-tumor efficacy of PD1 pathway blockade by promoting intra tumor immune response via immunogenic tumor cell death and T cell intrinsic mechanisms

T. Doman, E. Rasmussen, M. Kalos, 2018, Clinical Research (Excluding Clinical Trials).

Abstract 5245: Identification and characterization of the IDO1 inhibitor LY3381916

J. F. Schindler, M. Kalos, D. Clawson, 2018, Experimental and Molecular Therapeutics.

Arthralgia among women taking aromatase inhibitors: is there a shared inflammatory mechanism with co-morbid fatigue and insomnia?

Jinbo Chen, A. DeMichele, M. Kalos, 2015, Breast Cancer Research.

Abstract 2900: IMCgp100: A novel bi-specific biologic for the treatment of malignant melanoma

G. Linette, M. Kalos, C. June, 2014 .

Abstract 3525: IMCgp100: A novel bi-specific biologic for the treatment of malignant melanoma

G. Linette, M. Kalos, C. June, 2012 .

HIV conditionally replicating lentiviral vector expressing long antisense to Antiviral effects of autologous CD 4 T cells genetically modified with a

F. Bushman, L. Montaner, E. Papasavvas, 2013 .

GENE THERAPY Antiviral effects of autologous CD4 T cells genetically modiﬁed with a conditionally replicating lentiviral vector expressing long antisense to HIV

F. Bushman, L. Montaner, E. Papasavvas, 2013 .

A phase II, dose-optimization trial of autologous T cells genetically engineered to express anti-CD19 chimeric antigen receptor (CART-19) in patients with relapsed or refractory (r/r) CD19+ chronic lymphocytic leukemia (CLL).

D. Porter, B. Levine, M. Kalos, 2013 .

A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside.

D. Torigian, H. Nisenbaum, G. Coukos, 2013, Clinical cancer research : an official journal of the American Association for Cancer Research.

Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells.

M. Carroll, S. Grupp, D. Porter, 2014, Blood.

Striking Predictive Power For Relapse and Decreased Survival Associated With Detectable Minimal Residual Disease by IGH VDJ Deep Sequencing Of Bone Marrow Pre- and Post-Allogeneic Transplant In Children With B-Lineage ALL: A Subanalysis Of The COG ASCT0431/PBMTC ONC051 Study

C. Carlson, S. Grupp, M. Kalos, 2013 .

Conference scene: Immune signatures in the tumor and beyond.

G. Coukos, C. Melief, D. Speiser, 2012, Immunotherapy.

Cytokine Release Syndrome (CRS) after Chimeric Antigen Receptor (CAR) T Cell Therapy for Relapsed/Refractory (R/R) CLL

D. Teachey, S. Grupp, D. Porter, 2014 .

Identification and Characterization of Prostein , a Novel Prostate-specific Protein 1

S. Reed, M. Kalos, R. Houghton, 2001 .

A Dendritic Cell Vaccine Pulsed with Autologous Hypochlorous Acid-Oxidized Ovarian Cancer Lysate Primes Effective Broad Antitumor Immunity: From Bench to Bedside

D. Torigian, H. Nisenbaum, G. Coukos, 2013, Clinical Cancer Research.

Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells

Tyler J. Reich, F. Bushman, S. Carty, 2018, Nature.

T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans

B. Levine, M. Kalos, C. June, 2013, Cancer Immunology Research.

Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans.

M. Kalos, S. Forman, M. Jensen, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Charles J. Vaske, Joe Y. Chang, Scott R. Presnell, 2016, Journal for ImmunoTherapy of Cancer.